B

Broncus Holding Corp
HKEX:2216

Watchlist Manager
Broncus Holding Corp
HKEX:2216
Watchlist
Price: 0.46 HKD -1.08% Market Closed
Market Cap: 242.5m HKD
Have any thoughts about
Broncus Holding Corp?
Write Note

Broncus Holding Corp
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Broncus Holding Corp
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
B
Broncus Holding Corp
HKEX:2216
Accrued Liabilities
$4.5m
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Accrued Liabilities
ÂĄ132.8m
CAGR 3-Years
41%
CAGR 5-Years
42%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Accrued Liabilities
ÂĄ321.1m
CAGR 3-Years
38%
CAGR 5-Years
42%
CAGR 10-Years
49%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Accrued Liabilities
ÂĄ3.9B
CAGR 3-Years
15%
CAGR 5-Years
25%
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Accrued Liabilities
ÂĄ116.9m
CAGR 3-Years
14%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Accrued Liabilities
ÂĄ879.6m
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Broncus Holding Corp
Glance View

Market Cap
242.5m HKD
Industry
Health Care

Broncus Holding Corp. engages in provision of interventional diagnosis and therapeutics solutions. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2021-09-24. The firm's business includes providing diagnostic solutions, lung cancer treatment solutions, chronic obstructive pulmonary disease solutions and navigation platforms. The diagnostic solutions pruducts include FleXNeedle, ATV Sheath, ATV Balloon and others. The lung cancer treatment solutions products include InterVapor for lung cancer, H-Marker and others. The chronic obstructive pulmonary disease (COPD) solutions products include InterVapor for COPD and TLD Ablation System. The navigation platform products include Lungpoint, Lungpro, New Generation Navigation Platform and others.

Intrinsic Value
0.65 HKD
Undervaluation 29%
Intrinsic Value
Price
B

See Also

What is Broncus Holding Corp's Accrued Liabilities?
Accrued Liabilities
4.5m USD

Based on the financial report for Dec 31, 2023, Broncus Holding Corp's Accrued Liabilities amounts to 4.5m USD.

What is Broncus Holding Corp's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
-7%

Over the last year, the Accrued Liabilities growth was -8%. The average annual Accrued Liabilities growth rates for Broncus Holding Corp have been -7% over the past three years .

Back to Top